Celltrion won the patent suit and accelerated global commercialization over its breast cancer treatment

As Celltrion won the formulation patent suit over the original product of the breast cancer biosimilar ‘Herzuma,’ the company is now able to actively take procedures for its domestic sales and global commercialization.

According to Celltrion on the 21^st, the Intellectual Property Tribunal ruled nullity of the Herzuma’s original product of ‘Herceptin’ in the formulation patent suit. In other wo...